Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Renovacor logo — Advancing transformative therapies for cardiovascular diseas...

Renovacor

Advancing transformative therapies for cardiovascular disease

Founded 2019 6 employees Post-IPO Equity Total: $41.00M Biotechnology, Health Care +1

General Information

Company Name Renovacor
Founded Year 2019
Founders / Decision Makers
Team member
Employees 6
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Renovacor. To contact Renovacor, visit renovacor.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Renovacor compare?

A PDF of Renovacor and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Renovacor soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Renovacor

Renovacor is a biotechnology company founded in 2013 with the slogan "Advancing transformative therapies for cardiovascular disease." The company is focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases. Renovacor's lead program in BAG3-associated dilated cardiomyopathy (DCM) utilizes gene transfer technology to address the monogenic cause of this severe form of heart failure. Their vision is to bring life-changing therapies to patients living with serious genetic cardiovascular and related diseases by developing medicines that target the underlying cause of the disease. Their last investment of $30.00MPost-IPO Equity was injected on 03 September 2021, involving a diverse group of investors including Innogest Capital, Acorn Bioventures, Affinity Asset Advisors, Altium Capital, Ikarian Capital, Longview Ventures, RTW Investments, 683 CAPITAL, Chardan, and Surveyor Capital. Renovacor operates in the Biotechnology and Health Care industries, demonstrating a commitment to addressing the critical unmet needs in cardiovascular health. With a strong focus on transformative benefit and significant improvement to the quality of life, Renovacor is poised to make an impact in the development of precision therapies for cardiovascular diseases.

Business keywords: precision therapies, gene transfer technology, cardiovascular disease, gene therapy, dilated cardiomyopathy, BAG3 gene, preclinical-stage biopharmaceutical, recombinant adeno-associated virus (AAV), heart failure, orphan disease, genetic diseases, precision medicine, innovative therapies, transformational treatments

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $30.00M 10
Innogest Capital Acorn Bioventures Affinity Asset Advisors
Innogest Capital, Acorn Bioventures +8
03 Sep 2021
Series A $11.00M -
15 Aug 2019

Renovacor Alternatives & Competitors

View All Alternatives
Renovacor vs
Lexeo Therapeutics
Lexeo Therapeutics United States

Advancing science with curative potential for both cardiovascular and APOE4 associated Alzheimer's d...

Post-IPO Equity
97 employees
Biotechnology, Health and Wellness
Renovacor vs
AskBio Inc.
AskBio Inc. United States

Pioneering science to create transformative molecular medicines.

Grant
526 employees
Biopharma, Biotechnology
Renovacor vs
Solid Biosciences
Solid Biosciences United States

#TogetherWeAreSolid

Post-IPO Equity
161 employees
Biotechnology, Health Care
Also compare with: Renovacor vs Tenaya Therapeutics Tenaya Therapeutics Renovacor vs Atsena Therapeutics Atsena Therapeutics Renovacor vs Taysha Gene Therapies Taysha Gene Therapies View all alternatives

FAQ About Renovacor

Advancing transformative therapies for cardiovascular disease
Renovacor was founded in 2019.
Renovacor operates in Biotechnology, Health Care and Life Sciences. Its work centres on precision therapies, gene transfer technology, cardiovascular disease and gene therapy.
Renovacor has approximately 6 employees.
Renovacor has completed 2 funding rounds, raising a total of $41.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Renovacor include Lexeo Therapeutics, AskBio Inc., Solid Biosciences, Hunterian Medicine, Kate Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Renovacor and Lexeo Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Renovacor, https://bouncewatch.com/company/renovacor, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes